Sinnovi today announced that it has entered into an exclusive transfer agreement
with AmMax Bio for the global R&D and commercialization of an innovative antibody conjugate drug (ADC) for the treatment of solid tumors, except in Greater China.
Upon execution of the agreement, Cignova will receive payments of up to $871 million, including down payments and development, registration and sales milestones
.
In order to get out of the "inner volume", domestic pharmaceutical company license-out will continue to be hot! (Image source: Pharma Network)
It is reported that the exclusive transfer right agreement contains the license terms
negotiated between SignNova and AmMax.
At the same time, in accordance with this agreement, the two parties will collaborate to complete the clinical trial application (IND) of the collaborative project and the design of the dose-escalation clinical study, which is expected to be submitted to the IND application in China and the United States in mid-2023
.
It is worth mentioning that this is another license-out licensing cooperation
reached by Cignovi this year.
On January 6, Cignovi announced an exclusive worldwide licensing agreement
with METiS Therapeutics for the SOS1 inhibitor program.
Through the licensing agreement, METiS will receive exclusive global development and commercialization licenses for Synov's SOS1 inhibitor program, with Cignova receiving up to hundreds of millions of dollars in down payments and development, registration and sales milestone payments, as well as future royalties
based on a gradient share of global net annual sales.
The license-out model refers to the enterprise to carry out early drug research and development, and then authorize the project to other pharmaceutical companies for late-stage clinical research and development and marketing sales, and obtain clinical results at each stage and a certain percentage of sales share after commercialization according to the milestone model
.
In recent years, with the promotion of medical reform and drug reform, domestic innovative pharmaceutical enterprises License-out has begun to show continuous growth of heat
.
For example, in 2021, a number of innovative Chinese pharmaceutical companies granted overseas rights to multinational companies, in addition to BeiGene and Novartis' large deal
of up to US$2.
2 billion for tislelizumab.
The license-out of Innovent, Jacobio, Remegen and other companies has also brought tens of millions of dollars and hundreds of millions of dollars in milestones
.
In 2022, more and more small and medium-sized innovative pharmaceutical companies will join the License-out team, such as Hua Medicine in cooperation with Bayer and Platinum Pharmaceutical
in cooperation with AstraZeneca.
According to incomplete statistics, a total of 28 license-out projects were reached in 2022, including 20 innovative drug/new technology transaction projects, 4 biosimilar projects and 4 generic/improved new drug projects
.
From the current point of view, license-out transactions are mostly listed or late-stage clinical products, among which tumor immunity is a favored area
by multinational pharmaceutical companies.
The industry expects that with the introduction and landing of a series of policies to encourage the research and development of new drugs, the innovation vitality of China's biopharmaceutical industry will continue to increase, and at the same time, license-out will gradually become a stepping stone
for Chinese innovative drug companies to successfully "go overseas" and go international.
In the future, the competition in the domestic innovative drug market is becoming increasingly fierce, in order to get out of the "involution" and actively seek a way to break the situation, "going to sea" will undoubtedly become an important choice
for more pharmaceutical companies to find new market opportunities.
It is worth noting that in addition to the United States, the European market may gradually become a "dream place"
for more and more pharmaceutical companies to explore new opportunities.
It is reported that the PD-1 monoclonal antibody industry, which cannot stand the involution, has thrown a warm gaze
to Europe.
In April 2022, BeiGene's tislelizumab marketing authorization for esophageal squamous cell carcinoma and non-small cell lung cancer was accepted by EMA, becoming the first domestically produced PD-1 monoclonal antibody
to be submitted for marketing in Europe.
On November 15, Junshi also announced that its PD-1 inhibitor teripulimab has submitted two marketing authorization applications
to EMA.
In general, behind the continuous "going abroad" of domestic innovative drugs and constantly refreshing the total transaction value of overseas products, it can be seen that the strength of domestic innovative drug companies is rising, and the recognition of domestic innovative drug companies by multinational pharmaceutical companies is constantly improving
.
In the future, under the background of pharmaceutical companies continuing to increase investment in innovation and accelerate research and development, domestic innovative drugs will accelerate the "going global"
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
